Exclusive Summary

• First-in-Class Mechanism: UB040 is a multi-target small molecule immunostimulant that activates both innate and adaptive immunity while reversing the immunosuppressive Tumor Microenvironment (TME).
• Unique Non-Invasive Delivery: distinct from competitor injectables, UB040 offers Oral and Transdermal (patch/cream) formulations, significantly improving compliance and potentially reducing systemic toxicity.
• Strong Preclinical Proof-of-Concept: Demonstrated regression of both local and distant tumors (abscopal effect) and induction of long-term immune memory in difficult-to-treat models like KRAS-mutant PDAC and AML via topical application.

Asset Materials

Contact Us for Full Materials